Malignant Pleural Mesothelioma Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, and Companies by DelveInsight | Roche, AstraZeneca, Merck & Co, Amphera BV, Polaris Pharma

(Albany, United States) As per DelveInsight's assessment, globally, Malignant Pleural Mesothelioma pipeline constitutes 20+ key companies continuously working towards developing 20+ Malignant Pleural Mesothelioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Malignant Pleural Mesothelioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Mesothelioma Market.

The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Malignant Pleural Mesothelioma Pipeline Report:
• Malignant Pleural Mesothelioma Companies across the globe are diligently working toward developing novel Malignant Pleural Mesothelioma treatment therapies with a considerable amount of success over the years.
• Malignant Pleural Mesothelioma companies working in the treatment market are Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, AstraZeneca, Merck & Co, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others, are developing therapies for the Malignant Pleural Mesothelioma treatment
• Emerging Malignant Pleural Mesothelioma therapies in the different phases of clinical trials are- INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, Durvalumab, Pembrolizumab, MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), MTG201 + nivolumab, ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN, and others are expected to have a significant impact on the Malignant Pleural Mesothelioma market in the coming years.
• In February 2024, RS Oncology has initiated the dose expansion phase of its multicenter Phase II MITOPE clinical trial for RSO-021 in the UK, targeting malignant pleural mesothelioma and metastatic lung disease. This milestone underscores progress in RS Oncology's development of RSO-021, an investigational anti-cancer treatment designed to selectively target malignant cells by disrupting their antioxidant defenses.
• In December 2023, Sellas Life Sciences, a biopharmaceutical company in the late stages of clinical development based in the United States, has announced that its Phase I trial (NCT02737787) evaluating galinpepimut-S in combination with Opdivo (nivolumab) has successfully met its primary endpoint by demonstrating improved overall survival in patients with mesothelioma.
• In September 2023, based on results presented at the 2023 Best of ASCO Seattle from a Phase III study, Individuals diagnosed with malignant pleural mesothelioma, undergoing a chemoimmunotherapy protocol featuring the immune checkpoint inhibitor pembrolizumab, exhibited markedly enhanced overall survival in comparison to those subjected to chemotherapy alone, demonstrating acceptable tolerability.
• In May 2023, Verismo Therapeutics, a clinical-stage CAR-T company born out of the University of Pennsylvania, initiated the STAR-101 Phase 1 clinical trial at the university. The trial aims to assess the investigational new drug, SynKIR™-110, designed to target mesothelin-overexpressing malignant pleural mesothelioma, cholangiocarcinoma, and ovarian cancer. Verismo Therapeutics is conducting a multicenter Phase 1 clinical trial across these tumor types to investigate the feasibility and safety of SynKIR-110, as indicated by the ClinicalTrials.gov Identifier: NCT05568680.

Malignant Pleural Mesothelioma Overview
Malignant pleural mesothelioma is a rare and aggressive cancer that affects the thin layer of tissue (mesothelium) lining the lungs and chest cavity (pleura). It is primarily caused by exposure to asbestos fibers, typically occurring decades after initial exposure. Symptoms include chest pain, shortness of breath, and unexplained weight loss.

Get a Free Sample PDF Report to know more about Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Malignant Pleural Mesothelioma Drugs Under Different Phases of Clinical Development Include:
• INBRX-109: Inhibrx
• NX-1607: Nurix Therapeutics
• ATA2271: Atara Biotherapeutics
• TC-510: TCR2 Therapeutics
• RSO-021: RS Oncology
• SAR-444245: Sanofi
• Durvalumab: AstraZeneca
• Pembrolizumab: Merck & Co
• MesoPher: Amphera BV
• Pegargiminase: Polaris Pharmaceuticals
• Galinpepimut-S (Vaccine): Sellas Life Sciences Group
• MTG201 + nivolumab: Momotaro-Gene
• ZEPZELCA (lurbinectedin): PharmaMar
• IMFINZI: AstraZeneca
• ONCOS-102: Targovax
• TC-210: TCR2 Therapeutics
• TECENTRIQ Plus AVASTIN: Hoffmann-La Roche

Malignant Pleural Mesothelioma Route of Administration
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Malignant Pleural Mesothelioma Molecule Type
Malignant Pleural Mesothelioma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Malignant Pleural Mesothelioma Pipeline Therapeutics Assessment
• Malignant Pleural Mesothelioma Assessment by Product Type
• Malignant Pleural Mesothelioma By Stage and Product Type
• Malignant Pleural Mesothelioma Assessment by Route of Administration
• Malignant Pleural Mesothelioma By Stage and Route of Administration
• Malignant Pleural Mesothelioma Assessment by Molecule Type
• Malignant Pleural Mesothelioma by Stage and Molecule Type

DelveInsight's Malignant Pleural Mesothelioma Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Malignant Pleural Mesothelioma product details are provided in the report. Download the Malignant Pleural Mesothelioma pipeline report to learn more about the emerging Malignant Pleural Mesothelioma therapies at:
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Malignant Pleural Mesothelioma Therapeutics Market include:
Key companies developing therapies for Malignant Pleural Mesothelioma are - Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others.

Malignant Pleural Mesothelioma Pipeline Analysis:
The Malignant Pleural Mesothelioma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Mesothelioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma Treatment.
• Malignant Pleural Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Malignant Pleural Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Mesothelioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Malignant Pleural Mesothelioma drugs and therapies-
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Malignant Pleural Mesothelioma Pipeline Market Drivers
• Increased adoption of combination therapies are some of the important factors that are fueling the Malignant Pleural Mesothelioma Market.

Malignant Pleural Mesothelioma Pipeline Market Barriers
• However, treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem, high Cost of Treatment and other factors are creating obstacles in the Malignant Pleural Mesothelioma Market growth.

Scope of Malignant Pleural Mesothelioma Pipeline Drug Insight
• Coverage: Global
• Key Malignant Pleural Mesothelioma Companies: Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, AstraZeneca, Merck & Co, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others
• Key Malignant Pleural Mesothelioma Therapies: INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, Durvalumab, Pembrolizumab, MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), MTG201 + nivolumab, ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN, and others
• Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
• Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers

Request for Sample PDF Report for Malignant Pleural Mesothelioma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Malignant Pleural Mesothelioma Report Introduction
2. Malignant Pleural Mesothelioma Executive Summary
3. Malignant Pleural Mesothelioma Overview
4. Malignant Pleural Mesothelioma- Analytical Perspective In-depth Commercial Assessment
5. Malignant Pleural Mesothelioma Pipeline Therapeutics
6. Malignant Pleural Mesothelioma Late Stage Products (Phase II/III)
7. Malignant Pleural Mesothelioma Mid Stage Products (Phase II)
8. Malignant Pleural Mesothelioma Early Stage Products (Phase I)
9. Malignant Pleural Mesothelioma Preclinical Stage Products
10. Malignant Pleural Mesothelioma Therapeutics Assessment
11. Malignant Pleural Mesothelioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Malignant Pleural Mesothelioma Key Companies
14. Malignant Pleural Mesothelioma Key Products
15. Malignant Pleural Mesothelioma Unmet Needs
16 . Malignant Pleural Mesothelioma Market Drivers and Barriers
17. Malignant Pleural Mesothelioma Future Perspectives and Conclusion
18. Malignant Pleural Mesothelioma Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Bladder Cancer Market: https://www.delveinsight.com/report-store/bladder-cancer-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Biomarkers Testing Devices Market: https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Generalized Pustular Psoriasis Market: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Adult Myopia Market: https://www.delveinsight.com/infographics/adult-myopia-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Artificial Lung Devices Market: https://www.delveinsight.com/report-store/artificial-lung-devices-pipeline-insight-and-competitive-landscape
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Cardiac Amyloidosis Market: https://www.delveinsight.com/report-store/cardiac-amyloidosis-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Centronuclear Myopathy Market: https://www.delveinsight.com/report-store/centronuclear-myopathy-cnm-pipeline-insight
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Competitive Intelligence Pharma: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Cutaneous T Cell Lymphoma Market: https://www.delveinsight.com/infographics/cutaneous-t-cell-lymphoma-ctcl-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.